Actively Recruiting
Tirzepatide in Obesity-Driven Endometrial Cancer
Led by UNC Lineberger Comprehensive Cancer Center · Updated on 2026-04-28
20
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
LCCC2415 examines the antiproliferative effect of tirzepatide on the endometrium of endometrial cancer (EC). This is a pre-operative window clinical study. Endometrial biopsy samples from patients before tirzepatide treatment will be compared to their post-intervention hysterectomy specimens. If archival tissue is unavailable, a fresh biopsy will be taken before tirzepatide treatment. Post-intervention tissue will be collected from the hysterectomy specimen. The hypothesis is that tirzepatide's anti-tumorigenic effects are due to both an improvement in the host's metabolic milieu (indirect effect) and a direct effect on the EC tumor microenvironment via the inter-related pathways of insulin, lipid, and mTOR signaling. Therefore, tirzepatide may be an innovative approach to effectively induce weight loss and inhibit tumor growth in EC, the most obesity-driven of all cancers.
CONDITIONS
Official Title
Tirzepatide in Obesity-Driven Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Current diagnosis of endometrioid histology cancer and scheduled to undergo hysterectomy and staging.
- Agree to comply with all required study assessments and visits including internet capabilities.
- Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
- Age 65 18 at the time of consent.
- Body mass index of 65 30 kg/m2.
- Presumed clinically early-stage disease (disease confined to uterus only).
- ECOG 64 2 or Karnofsky Performance Status of > 50
You will not qualify if you...
- Active infection requiring systemic therapy.
- Subject is pregnant or breast feeding.
- Taking any prescription medications or other drugs that may influence metabolism per discretion of investigator.
- Taking a central nervous system stimulant.
- Current psychological conditions that would be incompatible with participation in this study, as determined by investigator.
- Known sensitivities (i.e., urticaria and eczema) to GIP and GLP-1 receptor agonists.
- Have type 1 diabetes mellitus or latent autoimmune diabetes in adults or receiving treatment with insulin.
- Have a history of severe hypoglycemia or not be able to communicate an understanding of hypoglycemic symptoms.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
Research Team
L
Luz Cuaboy
CONTACT
E
Emmie Cole
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here